Home > Insider Trading > Filing (0000950170-24-002945)

Filing Details

Accession Number:: 0000950170-24-002945
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-01-08 16:19:01
Reporting Period:: 2023-12-15

Accepted Time:: 2024-01-08 16:19:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650648	4D Molecular Therapeutics Inc.	FDMT	Biological Products, (No Disgnostic Substances) (2836)	473506994

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1834021	David Kirn	C/O 4D Molecular Therapeutics Inc. 5858 Horton Street #455 Emeryville CA 94608	Chief Executive Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-12-15	28,632	$17.27	1,230,521	No	4	S	Direct
Common Stock	Disposition	2023-12-18	4,702	$18.13	1,225,819	No	4	S	Direct
Common Stock	Disposition	2024-01-04	40,732	$20.31	1,185,087	No	4	S	Direct
Common Stock	Disposition	2024-01-05	28,104	$19.56	1,156,983	No	4	S	Direct
Common Stock	Disposition	2024-01-05	133	$20.11	1,156,850	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 17, 2023.
The transaction was executed in multiple trades in prices ranging from $17.00 to $17.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $17.77 to $18.525, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $20.02 to $20.545, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $19.085 to $20.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $20.09 to $20.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.